Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

University of Alberta discovers ERCC1 inhibitors

Jan. 4, 2021

Medshine Discovery discloses new FGFR/VEGFR2 dual inhibitors

Jan. 4, 2021

ShanghaiTech University patents ALK-targeting PROTACs

Jan. 4, 2021

Preclinical evaluation of SPR-519, a novel dual PI3K-alpha and mTOR kinase inhibitor

Dec. 31, 2020

Mirati Therapeutics describes new polycomb protein EED inhibitors

Dec. 31, 2020

New AXL/Mer/c-Met/VEGFR-2 inhibitors discovered at Exelixis

Dec. 31, 2020

Lanzhou University synthesizes siRNAs targeting OLFML2A

Dec. 31, 2020

Sulanda approved in China for non-pancreatic NETs

Dec. 31, 2020

Phase II results reported for AXL inhibitor bemcentinib in patients failing hypomethylating agents

Dec. 31, 2020

Activity against AML seen in vitro and in vivo with LSD1 inhibitor CPI-482

Dec. 31, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026